{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:34:16Z","timestamp":1792197256775,"version":"4.4.0"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3,20]]},"DOI":"10.1093\/jnci\/djt006","type":"journal-article","created":{"date-parts":[[2013,2,28]],"date-time":"2013-02-28T16:26:45Z","timestamp":1362068805000},"page":"405-423","source":"Crossref","is-referenced-by-count":70,"title":["Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1\u2013BCR-ABL\u2013JAK2 Complex"],"prefix":"10.1093","volume":"105","author":[{"given":"Min","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gallipoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"DeGeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Sloma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna L.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Ringrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Mi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Lambie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyi Min","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Turhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Arlinghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Stobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Eaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie J","family":"Eaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa L.","family":"Holyoake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,2,27]]},"reference":[{"key":"key\n\t\t\t\t20170520214105_CIT0001","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340(17)","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170520214105_CIT0002","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment","volume":"349(15)","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170520214105_CIT0003","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2010.159","article-title":"Insights into the stem cells of chronic myeloid leukemia","volume":"24(11)","author":"Sloma","year":"2010","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20170520214105_CIT0004","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2010.143","article-title":"Critical molecular pathways in cancer stem cells of chronic myeloid leukemia","volume":"24","author":"Chen","year":"2010","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20170520214105_CIT0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/shem.2003.50034","article-title":"Molecular mechanisms of transformation by the BCR-ABL oncogene","volume":"40(2 Suppl 2)","author":"Sattler","year":"2003","journal-title":"Semin Hematol"},{"key":"key\n\t\t\t\t20170520214105_CIT0006","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.20062335","article-title":"Oncogenic signaling: new insights and controversies from chronic myeloid leukemia","volume":"204(3)","author":"Van Etten","year":"2007","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170520214105_CIT0007","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-06-0025","article-title":"Janus kinase 2: a critical target in chronic myelogenous leukemia","volume":"66(13)","author":"Samanta","year":"2006","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t20170520214105_CIT0008","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5772\/29354","article-title":"Targeting the chronic myeloid leukemia stem cells: a paradigm for the curative treatment of human malignancies","volume-title":"Myeloid Leukemia\u2014Basic Mechanisms of Leukemogenesis","author":"Woolfson","year":"2011"},{"key":"key\n\t\t\t\t20170520214105_CIT0009","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/leu.2010.287","article-title":"Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia","volume":"25(3)","author":"Samanta","year":"2011","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20170520214105_CIT0010","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2(5)","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20170520214105_CIT0011","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355(213)","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170520214105_CIT0012","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305(5682)","author":"Shah","year":"2004","journal-title":"Science"},{"key":"key\n\t\t\t\t20170520214105_CIT0013","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7(2)","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t20170520214105_CIT0014","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293(5531)","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"key\n\t\t\t\t20170520214105_CIT0015","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105(7)","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0016","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jnci\/djk150","article-title":"Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells","volume":"99(9)","author":"Jiang","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20170520214105_CIT0017","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349(15)","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170520214105_CIT0018","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109(1)","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0019","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11(11)","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"10","key":"key\n\t\t\t\t20170520214105_CIT0020","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3324\/haematol.2012.062844","article-title":"Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials","volume":"97","author":"Tang","year":"2012","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20170520214105_CIT0021","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99(1)","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0022","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction","volume":"107(11)","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0023","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109(9)","author":"Jorgensen","year":"2007","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0024","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101(12)","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0025","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment","volume":"105(5)","author":"Chu","year":"2005","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0026","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118(20)","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0027","first-page":"2964","article-title":"Leukemic stem cell persistency in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"119(13)","author":"Chomel","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0028","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17(5)","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t20170520214105_CIT0029","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with Imatinib","volume":"21(2)","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t20170520214105_CIT0030","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.389","article-title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia","volume":"41(7)","author":"Chen","year":"2009","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20170520214105_CIT0031","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature09883","article-title":"BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition","volume":"473(7347)","author":"Duy","year":"2011","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170520214105_CIT0032","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121(3)","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20170520214105_CIT0033","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119(6)","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0034","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21(5)","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20170520214105_CIT0035","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.3816\/CLM.2007.s.005","article-title":"The challenges of targeting chronic myeloid leukemia stem cells","volume":"7(Suppl 2)","author":"Jiang","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"key\n\t\t\t\t20170520214105_CIT0036","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1182\/blood-2003-11-4026","article-title":"Deregulated expression in Ph+ human leukemias of AHI-1, a gene activated by insertional mutagenesis in mouse models of leukemia","volume":"103(10)","author":"Jiang","year":"2004","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0037","doi-asserted-by":"crossref","first-page":"918","DOI":"10.18632\/oncotarget.405","article-title":"AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders","volume":"12(12)","author":"Esmailzadeh","year":"2011","journal-title":"Oncotarget"},{"key":"key\n\t\t\t\t20170520214105_CIT0038","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1128\/JVI.76.18.9046-9059.2002","article-title":"Ahi-1, a novel gene encoding a modular protein with WD40-repeat and SH3 domains, is targeted by the Ahi-1 and Mis-2 provirus integrations","volume":"76(18)","author":"Jiang","year":"2002","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20170520214105_CIT0039","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1084\/jem.20072316","article-title":"AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem\/progenitor cells","volume":"205(11)","author":"Zhou","year":"2008","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170520214105_CIT0040","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.leu.2402225","article-title":"Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette","volume":"15(10)","author":"Dugray","year":"2001","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20170520214105_CIT0041","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood.V88.6.2162.bloodjournal8862162","article-title":"Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia","volume":"88(6)","author":"Petzer","year":"1996","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0042","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/sj.leu.2404189","article-title":"BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry","volume":"20(6)","author":"Hamilton","year":"2006","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20170520214105_CIT0043","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.leu.2404750","article-title":"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder- associated JAK2V617F and MPLW515L\/K mutations","volume":"21(8)","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20170520214105_CIT0044","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","article-title":"Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells","volume":"111(7)","author":"Wu","year":"2008","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0045","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101(2)","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0046","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase","volume":"100(13)","author":"Wu","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20170520214105_CIT0047","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1158\/0008-5472.CAN-10-2034","article-title":"Persistent activation of the Fyn\/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC","volume":"70(23)","author":"Fenouille","year":"2010","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t20170520214105_CIT0048","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94(6)","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0049","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2009-05-222471","article-title":"Properties of CD34+ CML stem\/progenitor cells that correlate with different clinical responses to imatinib mesylate","volume":"116(12)","author":"Jiang","year":"2010","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0050","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood.V92.4.1390","article-title":"The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic\/severe combined immunodeficiency mice reflect the phase of the donor\u2019s disease: an in vivo model of chronic myelogenous leukemia biology","volume":"92(4)","author":"Dazzi","year":"1998","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0051","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R\u03b3null mice engrafted with mobilized human hemopoietic stem cells","volume":"174(10)","author":"Shultz","year":"2005","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20170520214105_CIT0052","doi-asserted-by":"crossref","first-page":"6981","DOI":"10.1073\/pnas.0305894101","article-title":"Modular construction of a signaling scaffold: MORG1 interacts with components of the ERK cascade and links ERK signaling to specific agonists","volume":"101(18)","author":"Vomastek","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20170520214105_CIT0053","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1038\/emboj.2010.251","article-title":"The WD40-repeat protein Han11 functions as a scaffold protein to control HIPK2 and MEKK1 kinase functions","volume":"29(22)","author":"Ritterhoff","year":"2010","journal-title":"EMBO J"},{"key":"key\n\t\t\t\t20170520214105_CIT0054","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.biocel.2007.08.002","article-title":"An enhanced association of RACK1 with Abl in cells transfected with oncogenic ras","volume":"40(3)","author":"Huang","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"key":"key\n\t\t\t\t20170520214105_CIT0055","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/ng1419","article-title":"Corrigendum: Abnormal cerebellar development and axonal decussation due to mutations in AHI1 in Joubert syndrome","volume":"36(9)","author":"Ferland","year":"2004","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20170520214105_CIT0056","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ana.20749","article-title":"AHI1 gene mutations cause specific forms of Joubert syndrome-related disorders","volume":"59(3)","author":"Valente","year":"2006","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20170520214105_CIT0057","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1172\/JCI35339","article-title":"Huntingtin-associated protein 1 interacts with Ahi1 to regulate cerebellar and brainstem development in mice","volume":"118(8)","author":"Sheng","year":"2008","journal-title":"J Clin Invest"},{"issue":"12(8)","key":"key\n\t\t\t\t20170520214105_CIT0058","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"24","author":"O\u2019Hare","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key\n\t\t\t\t20170520214105_CIT0059","first-page":"428","article-title":"P210 Bcr-Abl interacts with the interleukin-3 beta c subunit and constitutively activates Jak2","volume":"11(Suppl 3)","author":"Wilson-Rawls","year":"1997","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20170520214105_CIT0060","doi-asserted-by":"crossref","first-page":"12804","DOI":"10.1073\/pnas.96.22.12804","article-title":"Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia","volume":"96(22)","author":"Jiang","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20170520214105_CIT0061","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","article-title":"Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation","volume":"109(5)","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0062","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117(12)","author":"Warsch","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0063","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","article-title":"The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors","volume":"117(12)","author":"Nelson","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0064","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"6(5)","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t20170520214105_CIT0065","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","article-title":"Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036","volume":"12(4)","author":"Chan","year":"2011","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t20170520214105_CIT0066","first-page":"48","article-title":"An approach to the management of chronic myeloid leukemia in British Columbia","volume":"15(2)","author":"Forrest","year":"2008","journal-title":"Curr Oncol"},{"key":"key\n\t\t\t\t20170520214105_CIT0067","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ccr.2008.02.017","article-title":"Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors","volume":"13(4)","author":"Geron","year":"2008","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t20170520214105_CIT0068","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13(4)","author":"Wernig","year":"2008","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t20170520214105_CIT0069","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-11-395228","article-title":"JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths","author":"Tefferi","year":"2012","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170520214105_CIT0070","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood.V95.6.2118","article-title":"STAT5 activation contributes to growth and viablility in Bcr\/Abl-transformed cells","volume":"95(6)","author":"Sillaber","year":"2000","journal-title":"Blood"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/105\/6\/405\/17312808\/djt006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T23:59:40Z","timestamp":1595462380000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/djt006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,27]]},"references-count":70,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,2,27]]},"published-print":{"date-parts":[[2013,3,20]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djt006","relation":{},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2,27]]}}}